^
Association details:
| Biomarker: | CDKN2B mutation |
|---|---|
| Cancer: | Urothelial Cancer |
| Drug Class: | Immunotherapy |
| Direction: | Resistant |
Evidence:
Source:
Title:
Association of biomarkers and outcomes in patients (pts) with metastatic urothelial carcinoma (mUC) treated with immune checkpoint inhibitors (ICIs).
Published date:
02/13/2023
Excerpt:
Among 152 mUC ICI-treated pts, 107 had NGS data (FoundationOne, UCSF500, Strata), including 85 with TMB data….Inferior outcomes were seen in pts with CDKN2B, KDM6A, FGF3, FGF4, and FGF19 alterations (Table).
DOI:
10.1200/JCO.2023.41.6_suppl.532
Source:
Title:
TERT promoter mutation as a prognostic marker in patients with advanced urothelial carcinoma treated with immune checkpoint inhibitors.
Published date:
02/08/2021
Excerpt:
We identified 78 pts treated with ICI for aUC with available genomic profiling results…n univariable analysis there was a trend towards longer OS in pts with TERTp mutations (HR 0.53, 95% CI 0.27-1.06, p = 0.07), and shorter OS in pts with CDKN2B mutations (HR 1.91, 95% CI 0.98-3.73, p = 0.06)....The presence of a TERTp mutation was an independent predictor of improved OS in a cohort of aUC pts treated with ICI.
DOI:
10.1200/JCO.2021.39.6_suppl.476
